Drugs / N-0923
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001931 | May 1999 → Jan 2001 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-0923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001931 ↗ |
| Action | Activate | “This dopamine receptor agonist will be administered transdermally under double-blind conditions, in a rising dose paradigm.” NCT00001931 ↗ |